Clinical Evidence: What UK Trials Show for Weight Loss
Ozempic vs Wegovy vs Mounjaro: Understanding UK Weight Loss Evidence
When comparing Ozempic vs Wegovy vs Mounjaro for weight loss results in the UK, it's crucial to understand the licensing differences first. Ozempic (semaglutide) is licensed exclusively for type 2 diabetes management and cannot be legally promoted for weight loss in the UK. However, Wegovy (also semaglutide) and Mounjaro (tirzepatide) are both MHRA-approved prescription-only medicines specifically for weight management in adults with a BMI ≥30, or BMI ≥27 with weight-related comorbidities. The clinical trial evidence for these treatments provides compelling insights into their effectiveness when used alongside a reduced-calorie diet and increased physical activity.
The distinction between these medications lies in their mechanisms and clinical outcomes. Wegovy works as a GLP-1 receptor agonist, whilst Mounjaro is a dual GIP/GLP-1 receptor agonist, offering a different approach to appetite regulation and glucose control. Both treatments have demonstrated significant weight loss results in their respective clinical trials, though direct head-to-head comparisons aren't available due to different trial designs and patient populations.
Wegovy vs Mounjaro Pricing: UK Weight Loss Investment
Understanding the cost comparison for Ozempic vs Wegovy vs Mounjaro weight loss treatments helps UK patients plan their investment in long-term weight management. At EverydayMeds, Wegovy pricing starts with the 0.25mg starter dose at £79.99, progressing through 0.5mg (£94.99), 1mg (£99.99), 1.7mg (£139.99), to the maintenance 2.4mg dose at £209.99. Our Getting Started bundles offer convenience, such as the Intro Duo (0.25mg & 0.5mg) for £169.99, providing your first two months of treatment in one order. New customers can apply discount code FIRST40 at checkout, whilst returning customers use code DOSE25.
Bundle options like our Progress Trio (0.5mg, 1mg & 1.7mg) at £369.99 ensure continuous supply during the critical dose escalation phase. For patients reaching maintenance therapy, the Ultimate Stability Trio provides three months of 2.4mg treatment for £649.99. These structured bundles eliminate the need for multiple orders and assurance treatment continuity, which research suggests is crucial for maintaining weight loss outcomes with GLP-1 receptor agonists.
Clinical Trial Results: Wegovy Weight Loss Evidence from STEP Studies
The STEP clinical trial programme provides robust evidence for Wegovy's effectiveness in weight management. In the landmark STEP 1 trial published by Wilding et al. in the New England Journal of Medicine (2021), participants taking Wegovy alongside lifestyle interventions achieved approximately 15% average weight loss at 68 weeks, compared to 2.4% with placebo. The STEP 3 trial demonstrated even greater results with intensive behavioural therapy, showing around 16% average weight loss.
Long-term sustainability data from STEP 5 revealed that patients maintained approximately clinically studied weight loss at two years, whilst the recent SELECT cardiovascular outcomes trial showed a 20% reduction in major cardiovascular events. These results consistently demonstrate that Wegovy may help support significant weight loss when used as part of a comprehensive weight management approach including dietary changes and increased physical activity.
How Wegovy Works: GLP-1 Mechanism in Ozempic vs Wegovy vs Mounjaro Comparison
Understanding the mechanism of action helps explain the weight loss results seen in Ozempic vs Wegovy vs Mounjaro comparisons. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics the natural incretin hormone GLP-1, which regulates appetite and food intake. When injected once weekly, Wegovy binds to GLP-1 receptors in the brain's appetite control centres, promoting feelings of fullness and reducing food cravings. This mechanism also slows gastric emptying, meaning food remains in the stomach longer, contributing to prolonged satiety after smaller meals. The medication works synergistically with dietary changes and increased physical activity to support sustainable weight management, rather than providing a standalone solution.
EverydayMeds Ordering Process: UK Wegovy Supply
Accessing Wegovy through EverydayMeds involves a streamlined three-step process designed for UK patients comparing Ozempic vs Wegovy vs Mounjaro options. Begin with our 3-minute online clinical assessment, which covers your medical history, current medications, and weight management goals to ensure Wegovy's suitability for your circumstances. Our qualified prescribers, working under GPhC registration #9012878, review your assessment within standard 3 working days, or 24 hours with our express service option. Once approved, your Wegovy is dispatched via next-day delivery using cold-chain transportation to maintain the medication's integrity throughout transit. This regulated process ensures you receive genuine, properly stored medication whilst meeting all MHRA requirements for prescription-only medicine supply.
Storage and Practical Considerations: Wegovy vs Mounjaro Advantages
Storage requirements represent a practical consideration when comparing Ozempic vs Wegovy vs Mounjaro for weight loss treatment in the UK. Wegovy must be stored in the refrigerator at 2-8°C before first use, but offers a significant advantage with up to 6 weeks of room temperature storage below 30°C once removed from the fridge, compared to Mounjaro's 21-day limit. This flexibility benefits UK patients who travel frequently or prefer not to refrigerate their weekly injection immediately. The FlexTouch pen delivery system provides consistent, accurate dosing throughout the mandatory dose escalation schedule, progressing from 0.25mg through to the 2.4mg maintenance dose over 16 weeks. Proper storage and adherence to the escalation protocol are essential for achieving the weight loss results demonstrated in clinical trials.
UK-Specific Weight Loss Outcomes: Regional Considerations for Treatment Success
Real-world weight loss results for Ozempic vs Wegovy vs Mounjaro in UK clinical practice may vary from international trial data due to regional dietary patterns, healthcare delivery differences, and population characteristics. UK patients often report particular success when combining Wegovy with NHS-recommended dietary approaches and local weight management support services, which may enhance the clinical trial outcomes observed in the STEP programme. The UK's seasonal variation and cultural eating patterns can influence treatment adherence and effectiveness, making ongoing clinical support particularly valuable.
Access to specialist weight management services through the NHS, combined with private prescription access via regulated pharmacies like EverydayMeds (GPhC #9012878), creates a comprehensive support framework for UK patients. This integrated approach may optimise the weight loss results achievable with prescription-only medicines, particularly when patients maintain consistent dosing schedules and engage with both medical supervision and lifestyle modification programmes tailored to UK dietary guidelines.
Making Your Choice: Wegovy Access Through EverydayMeds
Both Wegovy and Mounjaro are available through EverydayMeds, and your prescriber can help determine which treatment aligns best with your medical history and weight management goals when comparing Ozempic vs Wegovy vs Mounjaro options. Our clinical team provides ongoing support throughout your treatment journey, from initial assessment through dose escalation to maintenance therapy. Remember to apply discount code FIRST40 for new customers or DOSE25 for returning customers at checkout to access our competitive pricing structure. Visit https://everydaymeds.co.uk/collections/wegovy to begin your clinical assessment today, and join thousands of UK patients who have chosen evidence-based weight management solutions through our GPhC-registered pharmacy service. Start your transformation with the clinical evidence and professional support that makes sustainable weight loss achievable.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
